Abstract #302386

This is the preliminary program for the 2003 Joint Statistical Meetings in San Francisco, California. Currently included in this program is the "technical" program, schedule of invited, topic contributed, regular contributed and poster sessions; Continuing Education courses (August 2-5, 2003); and Committee and Business Meetings. This on-line program will be updated frequently to reflect the most current revisions.

To View the Program:
You may choose to view all activities of the program or just parts of it at any one time. All activities are arranged by date and time.

The views expressed here are those of the individual authors
and not necessarily those of the ASA or its board, officers, or staff.

Back to main JSM 2003 Program page
JSM 2003 Abstract #302386
Activity Number: 32
Type: Other
Date/Time: Sunday, August 3, 2003 : 4:00 PM to 5:50 PM
Sponsor: ASA
Abstract - #302386
Title: Statistical Considerations for Confirmatory Clinical Trials with Regulatory Objectives
Author(s): Gary G. Koch*+
Companies: University of North Carolina, Chapel Hill
Address: Department of Biostatistics, Chapel Hill, NC, 27599-7420,
Keywords:
Abstract:

This presentation addresses statistical considerations that substantially influence the design, analysis, and interpretation of confirmatory clinical trials with regulatory objectives. Some considerations that will be discussed include missing data and its implications to robustness of results, sufficiency of information to support efficacy of a test medicine through noninferiority to an active control, multiplicity of response variables, multiplicity of treatments, objectives for interim analyses, objectives for subgroups, and covariance adjustment in planned primary analyses. For all of these considerations, careful planning is necessary in order to have minimal bias in estimation, to avoid excessive prevalence of findings due to chance, and to have at least good power for the confirmatory demonstration of efficacy of a test medicine (through either the contradiction of a relevant null hypothesis or a convincingly located and narrow confidence interval). A critically important prerequisite for statistical strategies to address such objectives in a regulatory environment is their explicit specification in the protocol and formal analysis plan prior to any unmasking.

  • The address information is for the authors that have a + after their name.
  • Authors who are presenting talks have a * after their name.

Back to the full JSM 2003 program

JSM 2003 For information, contact meetings@amstat.org or phone (703) 684-1221. If you have questions about the Continuing Education program, please contact the Education Department.
Revised March 2003